| Objective:the formation and development of the tumor are closelyrelated with the cell differentive abnormalities and the apoptosis disorders.Themitochondrial serine protease Omi/HtrA2is a negative regulator of apoptosisinhibitory protein (IAPS).It can remove the IAPS inhibitoion ofapoptosis,and thus play an important role in the apoptosis. Esophagealcarcinoma is one of our nation's most high incidence of malignant tumors. Theincidence rate was16.7/100000, ranking5in various malignancies;211,000cases of death, mortality rate is13.4/100000, ranking No.4. Has been a lot ofresearch on the pathogenesis of esophageal cancer, that the development ofesophageal cancer by a number of genes involved in the process, many factorsplay an important role in the development of esophageal cancer, but the exactmechanisms are not yet detailed elucidated. It may be signifincance to revealthe evolutionary machanisms of the tumor cell development. The prognosis ofesophageal cancer is the focus of the present study. To investigate theexpression of the pro-apoptorsis fator Omi/HtrA2in esophageal cancertissues and adjacent noncancerous tissues and normal tissues to explore itsclinical significance with the type of clinical pathology and clinical stagingand prognosis.Methods:The expression of the mitochondrial serine proteaseOmi/HtrA2was assayed by immunohistochemistry En Vinsion system in40esophageal carcinoma tissues,40paracancerous tissues and13benignesophageal disease mucosa. The Omi/HtrA2positive expression showedyellow or brown. Specimens were taken from the Fourth Hospital of HebeiMedical University, Thoracic Surgery in Jan1,2005to Jun1,2006. All caseswere operationed,recorded integrity and completed follow-up and didnot preoperative chemotherapy, radiotherapy. All specimens were made of five micron serial sectioning, drying, dewaxing, hydration, antigen retrieval,incubation, color, radiography and other steps. The Omi/HtrA2positiveexpression appeared yellow or brown granules in the cytoplasm. Based onpositive staining intensity and the number of positive cells expressing,respectively, to judge the results.①Based on positive staining intensityjudgment: the cytoplasm did not stain, negative, noted0; pale yellow, note1;yellow, marked2; brownish yellow in the cytoplasm, three points.②thenumber of scoring based on the positive expression: light microscope at400times the10different field of view, no positive expression, noted0point;positive expesson area≤25%, note1point;25%-50%note2points;≥50%note3points. The scoring results of the two judge product for the finalscoring results. The final scoring results:<3is negative,≥3points is positive;3-4point is positive (+),6-9point is strong positive (++). StatisticallySPSS13.0software for statistical analysis, include Chi square test and Fishertest; survival rate using Kaplan-Meier method and Log-rank test.Results:1Studies have shown that the Omi/HtrA2positive products were localized inthe cytoplasm, the positive expression apear yellow or brown. The positiverate of Omi/HtrA2expression in esophageal carcinoma was70.00percent, inthe paracancerous tissues was27.50percent,in the mucosa of benignesophageal disease was23.08percent. Omi/HtrA2expression in esophagealcarcinoma tissues was significantly higher than the paracancerous tissues andbenign esophageal disease mucosa. Further analysis,esophageal cancer tissuescompared with paracancerous tissues significant difference by statistically (P<0.01), statistical comparison between the cancer tissue and benignesophageal disease mucosa is significant differences (P <0.01), indicating thecancer tissue Omi/HtrA2expression is significantly higher than theparacancerous tissues, the mucosal tissue of benign esophageal disease.Compared with benign esophageal disease mucosa and paracancerous tissueshas no statistically difference (P>0.05).2The expression rate of Omi/HtrA2in esophageal carcinoma tissues was relationship with the differentiated degree of tumor histology (P <0.05).Thepositive rate of Omi/HtrA2was83.3percent in the well and moderatelydifferentiated tumor tissues,in the pooly differentiated tumor tissues was50percent.(P <0.05). The Omi/HtrA2expression in esophageal carcinomashowed no correlation with age, gender, location (P>0.05),but correlationwith depth of invasion, lymph node metastasis, clinical stages (P <0.05). Thepositive expression of Omi/HtrA2was80.00%in early clinical stage (T1+T2), positive expression rate in clinical stage (T3+T4) was60.00%, thestatistically difference was significant(P <0.05); the positive rate ofOmi/HtrA2was88.23%in no lymph node metastasis group, the positiveexpression rate of lymph node metastas group was56.52%.There was also asignificant difference betweent these two groups(<0.05).3The Omi/HtrA2positive expression group,5-year survival rate was47.8%,the5-year survival of the negative expression group was15.00%, the total5-year survival rate was44%. By the Kaplan-Meier single factor analysis andLog-Rank test, we found that the survival difference between two groups wassignificant (P=0.029, P <0.05).Conclusion:1The high expression of Omi/HtrA2in esophageal carcinoma may promoteapoptosis and play an important role in the progression.2The Omi/HtrA2expression in esophageal carcinoma was relationship withpathological grading and depth of invasion, lymph node metastasis, clinicalstages.35-year survival rate of Omi/HtrA2positive expression was significantlyhigher than the negative expression group.That may be becanse Omi/HtrA2high expression promote apoptosis of the tumor tissue,and thus has certaineffect to patients long-term survival.And reduced the tumor recurrence orpotential metastasis. |
PDF Full Text Request